Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.69 CAD | -1.82% |
|
+16.96% | -0.37% |
26/06 | Nervgen Pharma Initiated at Market Perform, $3 Price Target at Raymond James | MT |
25/06 | NervGen Pharma to Advance New Drug Candidate into Preclinical Proof-of-Concept Stage | MT |
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Michael Kelly
CEO | Chief Executive Officer | 59 | 10/23/10 |
Bill Adams
DFI | Director of Finance/CFO | 62 | 24/20/24 |
Daniel Mikol
CTO | Chief Tech/Sci/R&D Officer | - | 05/21/05 |
Adam Rogers
BRD | Director/Board Member | - | 14/22/14 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Randall Kaye
BRD | Director/Board Member | 61 | 28/20/28 |
Brian Bayley
BRD | Director/Board Member | 71 | 16/18/16 |
Michael Kelly
CEO | Chief Executive Officer | 59 | 10/23/10 |
Harold Punnett
FOU | Founder | 67 | 19/17/19 |
John Thompson
BRD | Director/Board Member | 57 | 13/22/13 |
John Ruffolo
BRD | Director/Board Member | - | 17/23/17 |
Glenn Ives
CHM | Chairman | 62 | 01/21/01 |
Adam Rogers
BRD | Director/Board Member | - | 14/22/14 |
Director/Board Member | - | 01/21/01 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 69,977,649 | 53,864,835 ( 76.97 %) | 0 | 76.97 % |
Company contact information
NervGen Pharma Corp.
112-970 Burrard Street Unit 1290
V6Z 2R4, Vancouver
+778-731-1711
http://www.nervgen.com![address NervGen Pharma Corp.(NGEN)](https://cdn.zonebourse.com/static/address/55763923.png)
Sector
Sales per region
![Consensus](/images/consensus_flch.gif)
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-0.37% | 140M | |
+38.65% | 39.1B | |
-8.62% | 38.76B | |
+26.95% | 31.24B | |
+10.74% | 25.9B | |
-13.50% | 25.8B | |
+44.87% | 14.06B | |
+34.36% | 13.12B | |
-7.14% | 11.32B | |
-12.61% | 10.68B |
- Stock Market
- Equities
- NGEN Stock
- Company NervGen Pharma Corp.